Collectively, our study reveals that IP3R1 in skeletal muscle and adipocytes exerts divergent effects on obesity and obesity-related metabolic disorders and provides a rational basis for developing adipocyte IP3R1 as a promising target for the treatment of obesity and type 2 diabetes. The gene discussed is ITPR1; the disease is metabolic disease.